- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
Patent holdings for IPC class A61K 38/48
Total number of patents in this class: 3759
10-year publication summary
321
|
359
|
350
|
395
|
402
|
350
|
389
|
334
|
325
|
97
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Allergan, Inc. | 2600 |
162 |
Ipsen Biopharm Limited | 263 |
65 |
Talengen International Limited | 85 |
63 |
MERZ PHARMA GmbH & CO. KGaA | 624 |
61 |
Baxter International Inc. | 2425 |
37 |
The Regents of the University of California | 18943 |
34 |
Curemark, LLC | 78 |
34 |
Bioverativ Therapeutics Inc. | 220 |
33 |
Revance Therapeutics, Inc. | 161 |
33 |
Takeda Pharmaceutical Company Limited | 2961 |
31 |
The Children's Hospital of Philadelphia | 716 |
30 |
Baxter Healthcare S.A. | 1810 |
29 |
Translate bio, Inc. | 394 |
29 |
Omrix Biopharmaceuticals Ltd. | 159 |
28 |
HANSA Biopharma AB | 67 |
28 |
Modernatx, Inc. | 1181 |
27 |
Penland Foundation | 35 |
27 |
Talengen Institute of Life Sciences Co., Ltd. | 28 |
25 |
Alexion Pharmaceuticals, Inc. | 606 |
23 |
Ipsen Bioinnovation Limited | 57 |
23 |
Other owners | 2937 |